PARP7抑制:在癌症治疗方面取得进展的有希望的途径
1Usona Institute, Fitchburg, Wisconsin 53711-5300, United States.
ACS medicinal chemistry letters
|September 22, 2023
概括
新的研究突出了癌症治疗中潜在的PARP7抑制剂. 这些化合物可能会恢复免疫反应并促进瘤回归,为各种癌症提供新的治疗途径.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 药物发现 药物发现 药物发现
背景情况:
- 尽管治疗进展,但卵巢癌的生存率仍然很低.
- 聚 (ADP-ribose) 聚合酶 (PARP) 抑制剂表现有前途,但面临诸如耐药性等挑战.
- PARP7正在成为癌症治疗的新目标.
研究的目的:
- 突出针对PARP7.7的新型化合物和配方.
- 探索PARP7抑制剂在恢复抗瘤免疫反应中的潜力.
- 确定癌症和免疫疾病的新治疗策略.
主要方法:
- 对针对PARP7.7的化合物和配方的专利分析.
- 综述表明PARP7抑制剂对干扰素信号传递的影响的研究.
- 对瘤回归和癌症治疗潜力的评估.
主要成果:
- 鉴定具有强烈PARP7抑制活性的化合物和配方.
- 证明PARP7抑制可以恢复I型干扰素信号传递.
- 在临床前模型中瘤回归的证据.
结论:
- PARP7 抑制剂代表了一个有前途的新疗法类别.
- 这些抑制剂可以克服PARP抑制剂的现有挑战.
- PARP7 抑制剂具有治疗各种癌症和免疫疾病的潜力.
更多相关视频
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K


